Head-To-Head Comparison: CannaPharmaRX (OTCMKTS:CPMD) versus Savara (NASDAQ:SVRA)

CannaPharmaRX (OTCMKTS:CPMD) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Earnings and Valuation

This table compares CannaPharmaRX and Savara’s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CannaPharmaRX	N/A	N/A	-$8.53 million	($0.03)	-0.60
Savara	N/A	N/A	-$54.70 million	($0.33)	-14.55

Savara is trading at a lower price-to-earnings ratio than CannaPharmaRX, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for CannaPharmaRX and Savara, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CannaPharmaRX	0	0	0	0	N/A
Savara	0	0	5	0	3.00

Savara has a consensus price target of $8.20, indicating a potential upside of 70.83%. Given Savara’s higher probable upside, analysts plainly believe Savara is more favorable than CannaPharmaRX.

Risk & Volatility

CannaPharmaRX has a beta of 2.1, meaning that its stock price is 110% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Profitability

This table compares CannaPharmaRX and Savara’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CannaPharmaRX	N/A	N/A	-141.66%
Savara	N/A	-46.27%	-35.94%

Institutional and Insider Ownership

97.3% of Savara shares are owned by institutional investors. 1.3% of CannaPharmaRX shares are owned by company insiders. Comparatively, 4.6% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About CannaPharmaRX

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.

About Savara

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.